MX381841B - Anticuerpos anti-jagged y métodos de uso. - Google Patents

Anticuerpos anti-jagged y métodos de uso.

Info

Publication number
MX381841B
MX381841B MX2018004827A MX2018004827A MX381841B MX 381841 B MX381841 B MX 381841B MX 2018004827 A MX2018004827 A MX 2018004827A MX 2018004827 A MX2018004827 A MX 2018004827A MX 381841 B MX381841 B MX 381841B
Authority
MX
Mexico
Prior art keywords
methods
jagged
anitbodies
same
disclosure provides
Prior art date
Application number
MX2018004827A
Other languages
English (en)
Spanish (es)
Inventor
Christian W Siebel
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX381841B publication Critical patent/MX381841B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2018004827A 2012-08-13 2013-08-13 Anticuerpos anti-jagged y métodos de uso. MX381841B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682640P 2012-08-13 2012-08-13
US201361784332P 2013-03-14 2013-03-14
PCT/US2013/054664 WO2014028446A1 (en) 2012-08-13 2013-08-13 Anti-jagged anitbodies and methods of use

Publications (1)

Publication Number Publication Date
MX381841B true MX381841B (es) 2025-03-13

Family

ID=49004047

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004827A MX381841B (es) 2012-08-13 2013-08-13 Anticuerpos anti-jagged y métodos de uso.
MX2015001942A MX357675B (es) 2012-08-13 2013-08-13 Anticuerpos anti-jagged y métodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015001942A MX357675B (es) 2012-08-13 2013-08-13 Anticuerpos anti-jagged y métodos de uso.

Country Status (10)

Country Link
US (4) US10113002B2 (enExample)
EP (1) EP2882776B1 (enExample)
JP (4) JP6352264B2 (enExample)
KR (2) KR102193080B1 (enExample)
CN (1) CN104520328B (enExample)
BR (1) BR112015003032B1 (enExample)
CA (1) CA2880271C (enExample)
MX (2) MX381841B (enExample)
RU (2) RU2666990C2 (enExample)
WO (1) WO2014028446A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030170636A1 (en) * 2002-03-05 2003-09-11 Isis Pharmaceuticals Inc. Antisense modulation of jagged 2 expression
US20030185829A1 (en) * 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
CA2496547A1 (en) 2002-08-29 2004-03-11 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2546017A1 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
WO2008140826A1 (en) * 2007-05-15 2008-11-20 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
JP2009078998A (ja) * 2007-09-26 2009-04-16 Univ Of Tokushima Ｊａｇｇｅｄ２を用いる制癌剤
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
MX2011002928A (es) 2008-10-01 2011-04-11 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8945569B2 (en) * 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition

Also Published As

Publication number Publication date
US20200377610A1 (en) 2020-12-03
JP6619047B2 (ja) 2019-12-11
CA2880271C (en) 2021-10-19
BR112015003032A8 (pt) 2018-04-10
JP6352264B2 (ja) 2018-07-04
BR112015003032A2 (pt) 2017-12-12
JP7366700B2 (ja) 2023-10-23
CN104520328B (zh) 2019-06-07
RU2015108797A (ru) 2016-10-10
HK1209432A1 (en) 2016-04-01
JP2018139595A (ja) 2018-09-13
EP2882776A1 (en) 2015-06-17
EP2882776B1 (en) 2018-05-02
KR20200143502A (ko) 2020-12-23
MX357675B (es) 2018-07-18
US20150232568A1 (en) 2015-08-20
CA2880271A1 (en) 2014-02-20
RU2666990C2 (ru) 2018-09-13
RU2018130986A (ru) 2018-10-09
US20190135936A1 (en) 2019-05-09
JP2021191275A (ja) 2021-12-16
WO2014028446A1 (en) 2014-02-20
BR112015003032B1 (pt) 2023-03-28
US10689455B2 (en) 2020-06-23
US20240034805A1 (en) 2024-02-01
US10113002B2 (en) 2018-10-30
KR20150041656A (ko) 2015-04-16
JP2020048563A (ja) 2020-04-02
MX2015001942A (es) 2015-08-14
US11702479B2 (en) 2023-07-18
JP2015530989A (ja) 2015-10-29
KR102193080B1 (ko) 2020-12-18
CN104520328A (zh) 2015-04-15
RU2018130986A3 (enExample) 2021-12-22

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MY191169A (en) Anti-fcrh5 antibodies
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12016501143A1 (en) Anti-cd33 antibodies and immunoconjugates
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2020008436A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.